Dupixent Posts Positive Results in Phase III Pediatric Asthma Study

Dupixent continues to demonstrate its abilities to benefit asthma patients. In a Phase III study, the biologic met primary and all key secondary endpoints in children ages 6 to 11 who have uncontrolled moderate-to-severe asthma.